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econsidering Combined
ntiplatelet and Anticoagulant
herapy in Atrial Fibrillation*
odney H. Falk, MD, FACC
oston, Massachusetts
ith the publication in 1989 of the first large randomized
ontrolled trial of warfarin in atrial fibrillation (1), the role
f anticoagulation for preventing stroke in this arrhythmia
ecame established. Subsequent trials, published during the
ollowing decade, confirmed the efficacy of the coumarin
nticoagulants and demonstrated that stroke risk was a
unction not only of the arrhythmia but also of the associ-
ted underlying heart disease. Also shown was a narrow
indow for warfarin therapy above which serious bleeding
ncreased and below which efficacy was reduced (2). The
esults of trials directly comparing aspirin with coumarin
nticoagulation suggested that aspirin may have a modest
ffect in reducing stroke and was probably associated with a
esser risk of intracranial bleeding (2). However, the mag-
itude of any aspirin effect in atrial fibrillation is relatively
mall, and it is not an adequate substitute for warfarin for
troke prevention.
See page 1557
Atrial fibrillation is a disorder of older patients, and the
lderly often have comorbidities that may increase the
leeding risk of long-term warfarin use. With this in mind,
ombinations of fixed low-dose warfarin plus aspirin were
xplored in the hope that bleeding would be reduced while
educing stroke risk to a similar degree as adjusted-dose
arfarin. This hypothesis was resoundingly disproved by the
troke Prevention in Atrial Fibrillation (SPAF) III inves-
igators, who found a four-fold greater stroke risk among
atients with atrial fibrillation who were treated with
inidose warfarin (mean international normalized ratio
INR] 1.3) and 325 mg of aspirin daily compared with those
eceiving adjusted-dose warfarin with a mean INR of 2.4
3). A subsequent well-designed case-control study con-
rmed that the optimal INR for stroke reduction was 2.0
nd noted a doubling and tripling of stroke risk as the INR
ecreased to 1.7 and 1.5, respectively (4). These observa-
ions seemed to herald the death knoll for a role of
ntiplatelet agents in preventing stroke for the majority of
atients with atrial fibrillation.
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.m
From the Department of Cardiology, Harvard Vanguard Medical Associates,
oston, Massachusetts.With the publication of the National Study for Preven-
ion of Embolism in Atrial Fibrillation (NASPEAF), in this
ssue of the Journal, Pérez-Gómez et al. (5) have challenged
his negative view of antiplatelet agents. Following in the
ootsteps of investigators who demonstrated a highly signif-
cant benefit of adding aspirin to therapeutic warfarin in
atients with mechanical valves (6), they performed an
pen-label, unblinded but randomized comparison of the
ntiplatelet agent triflusal alone, acenocoumarol alone, or
he combination of the two drugs. Acenocoumarol is a
itamin K antagonist commonly used in Europe, whereas
riflusal is a less widely used antiplatelet agent that is
tructurally related to aspirin. Like aspirin, triflusal is an
nhibitor of platelet arachidonic acid metabolism, resulting
n an irreversible inhibition of platelet cyclooxygenase.
owever, unlike aspirin, it has little effect on vascular
ndothelial arachidonic acid metabolism and, hence, it does
ot affect prostacyclin synthesis (7). In clinical trials, it was
onsistently associated with a lower risk of bleeding than
spirin (8–10), and observational studies suggest less risk of
astrointestinal bleeding than that which occurs with aspirin
11).
In the currently reported trial, patients were divided into
ntermediate-risk and high-risk groups for thromboembo-
ism, with the high-risk group defined as patients with
ither a previous neurologic event or the presence of mitral
tenosis. After stratification, subjects were randomized to
djusted-dose acenocoumarol alone (target INR 2 to 3) or to
00 mg of triflusal daily plus acenocoumarol with a target
NR of 1.25 to 2.0 in the intermediate-risk group and 1.4 to
.4 in the high-risk group. A third arm was included in the
ntermediate-risk group consisting of triflusal 600 mg alone.
he median INR for the combination therapy in the
ntermediate- and high-risk groups was 1.93 and 2.17,
espectively. Combined therapy resulted in a statistically
ignificant lower primary event rate in both the high- and
ntermediate-risk groups and demonstrated the benefits of
riflusal therapy added to acenocoumarol in patients with
oderate-to-high risk of embolic events from atrial fibril-
ation. Although severe bleeding, defined as bleeding re-
uiring hospital admission, transfusion, or surgery, occurred
ore commonly in the arm receiving combined therapy, 9
f the 14 intracranial hemorrhages occurred in the group
eceiving anticoagulation alone.
The NASPEAF is unique in including patients with
itral stenosis because as all large previous trials of anti-
hrombotic therapy in atrial fibrillation excluded patients
ith valvular disease because of the concern of a dispropor-
ionately high risk of stroke. The NASPEAF data, along
ith the results of a recently published small trial (12),
rovide important information referable to mitral stenosis.
mong all patients receiving anticoagulation with a target
NR of 2 to 3, the stronger predictor of an end point was the
resence of a previous embolism rather than the presence of
itral stenosis, thereby underscoring the importance of
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Editorial Comment October 19, 2004:1567–9igorous antithrombotic therapy among patients with a
rior atrial fibrillation-related stroke. The findings also
alidate consensus recommendations extrapolated from tri-
ls of nonvalvular atrial fibrillation, that warfarin anticoag-
lation in patients with atrial fibrillation and mitral stenosis
hould be targeted to an INR of 2.0 to 3.0 (13).
Do the NASPEAF data support the benefit of combining
ntiplatelet therapy with coumarin anticoagulation targeted
o a slightly lower INR than the current recommendation of
.0 to 3.0? Based on their interpretation of the results of this
tudy, Pérez-Gómez et al. (5) suggest that, “an INR of 2,
onsidered . . . the lower limit of safety during anticoagula-
ion therapy, is not applicable to patients on combined
herapy.” In my opinion, this conclusion is premature.
lthough in the high-risk group receiving combination
herapy, 39% of INR measurements were 2.0, the median
NR for this group was 2.17, and 21% of INR measure-
ents in the standard anticoagulation arm were also 2.0.
e do not, however, know how much lower than 2.0 these
alues decreased, how much of the time any individual
atient’s measurements was less than this value, nor what
he INR was at the time of an embolic event. In the absence
f this information to evaluate the authors’ claim of safety of
lower INR than is recommended for coumarin anticoag-
lation alone, it is prudent to still maintain an INR of at
east 2.0 in a coumarin-antiplatelet combination.
Are the results of NASPEAF applicable to warfarin and
spirin, the respective anticoagulant and antiplatelet agents
ost commonly used in the U.S.? Warfarin and acenocou-
arol are both vitamin K antagonists, and clinical trials
sing either of these agents show similar benefits for a
imilar prolongation of INR. Thus, it is reasonable to
onsider data obtained with either of these two agents as
nterchangeable. In contrast, triflusal and aspirin differ from
ne another despite a structural relationship (7). Several
linical trials have compared the two agents, including
tudies in patients with recent myocardial infarction (10)
nd stroke or transient ischemic attack (8,9). A double-
lind trial of 600 mg of triflusal versus aspirin 300 mg daily,
tarted within 24 h of myocardial infarction and continued
or 35 days, found no significant difference in a combined
nd point of death, nonfatal myocardial reinfarction, or
onfatal cerebrovascular events, but significantly fewer cen-
ral nervous system bleeding episodes occurred in triflusal-
reated patients (10). In a 431-patient pilot trial for the
revention of stroke after an episode of cerebral ischemia,
he two drugs were similar in efficacy (9), and in a larger trial
f 2,113 patients with recent cerebrovascular events, no
enefit of triflusal over aspirin was found when a combined
nd point of nonfatal ischemic stroke, acute myocardial
nfarction, or vascular death was evaluated (8). However,
ajor hemorrhage (defined as that requiring hospital ad-
ission and/or transfusion) was significantly lower in the
riflusal group, leading to an estimate that the substitution
f triflusal for aspirin in such patients would result in 24 Eewer major hemorrhagic events per thousand patients
reated than would occur if 325 mg of aspirin were used (8).
It is unfortunate, although understandable, that there was
ot a warfarin-aspirin arm in NASPEAF, but it appears
easonable, given their equivalent efficacy in other cardio-
ascular diseases, to conclude that aspirin may reduce
schemic stroke risk if combined with therapeutic warfarin in
atients with atrial fibrillation. Indeed, this combination has
een effective in patients with prosthetic valves (6). How-
ver, based on the slight but consistently greater bleeding
isk of aspirin over triflusal, might the higher bleeding risk
ncountered with patients on aspirin offset any benefit of the
ombination? In the trials in which triflusal has been
ompared with aspirin, the aspirin dose was usually 325 mg,
hereas the addition of 75 mg of aspirin to warfarin in a
ecent postmyocardial infarction trial did not increase the
leeding risk compared with warfarin therapy alone (14). In
meta-analysis of trials of warfarin and aspirin for patients
ith prosthetic heart valves (6), the combination of warfarin
nd aspirin was more effective in preventing thromboem-
olism than was warfarin alone, and low-dose aspirin (100
g daily) was no less effective than higher doses. Further-
ore, there appeared to be a lesser risk of bleeding with
spirin when used at 100 mg daily in conjunction with
arfarin compared with the higher dose combination, and
here was no excess in major bleeding over warfarin alone in
wo large trials using 100 mg combined with warfarin (6).
Thus, 100 mg of aspirin has an equivalent efficacy in
atients with cardiac disease compared with higher aspirin
oses, and aspirin is not inferior to triflusal in head-to-head
omparisons. Aspirin appears to be a relatively safe drug to
dd to warfarin with a target INR of 2 to 3, and the
ombination is of demonstrable benefit in preventing
hromboembolism from mechanical valves. Based on these
ata and until more direct data are available, the clinician
an, in my opinion, extrapolate from the NASPEAF to
ustify the addition of aspirin to therapeutic doses of
arfarin in selected patients with atrial fibrillation. One
uch group would be those with recurrent embolic events
espite adequate warfarin therapy. Others would be patients
ith atrial fibrillation and a prior stroke or transient isch-
mic attack, even if it occurred when the patient was not on
ntithrombotic therapy, because such patients are at high
isk of a recurrent events (15) and are imperfectly protected
y coumarin anticoagulation alone (5). For other patients,
he potential risk-benefit is less clear, and we will have to
wait either a trial of the combination of therapeutic
arfarin and low-dose aspirin or for the more widespread
vailability of triflusal.
eprint requests and correspondence: Dr. Rodney H. Falk,
epartment of Cardiology, Harvard Vanguard Medical Asso-
iates, 133 Brookline Avenue, Boston, Massachusetts 02215.
-mail: rfalk@partners.org.
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